CLINICAL TRIALS PROFILE FOR RANITIDINE BISMUTH CITRATE

All Clinical Trials for RANITIDINE BISMUTH CITRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00985608 ↗	Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study	Unknown status	Catholic University of the Sacred Heart	Phase 2	2009-04-01	H pylori gastric infection is one of the most prevalent infectious diseases worldwide. The discovery that most upper gastrointestinal diseases are related to H pylori infection and therefore can be treated with antibiotics is an important medical advance. Currently, a first-line triple therapy based on proton pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus two antibiotics (clarithromycin and amoxicillin or nitroimidazole) is recommended by all consensus conferences and guidelines. Even with the correct use of this drug combination, infection can not be eradicated in up to 23% of patients. Therefore, several second line therapies have been recommended. A 7 d quadruple therapy based on PPI, bismuth, tetracycline and metronidazole is the more frequently accepted. However, with second-line therapy, bacterial eradication may fail in up to 40% of cases. When H pylori eradication is strictly indicated the choice of further treatment is controversial. When available, endoscopy with culture and consequent antibiotic susceptibility testing remains the most appropriate option for patients with two eradication failures to avoid a widespread use of expensive antibiotics. The use of these drugs may also induce severe side-effects and development of H pylori resistant strains. Resistant strains of Helicobacter pylori can display a dense biofilm with mucus and microorganisms in a coccoid shape on the mucosal surface of stomach that may have a role in determining the resistance to the antibiotic therapies. Possibly, N-acetil-cysteine (NAC) may dissolve biofilm architecture and help to eradicate resistant strains of H pylori.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02555852 ↗	Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	Completed	Canadian Institutes of Health Research (CIHR)		2011-09-01	The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP). The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.
NCT02555852 ↗	Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	Completed	Drug Safety and Effectiveness Network, Canada		2011-09-01	The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP). The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.

Clinical Trial Conditions for RANITIDINE BISMUTH CITRATE

Condition Name

Condition Name for RANITIDINE BISMUTH CITRATE
Intervention	Trials
GERD	1
Helicobacter Pylori Infection	1
Metastatic Cancer	1
Atrial Fibrillation	1

Condition MeSH

Condition MeSH for RANITIDINE BISMUTH CITRATE
Intervention	Trials
Atrial Fibrillation	1
Infections	1
Infection	1
Helicobacter Infections	1

Clinical Trial Locations for RANITIDINE BISMUTH CITRATE

Trials by Country

Trials by Country for RANITIDINE BISMUTH CITRATE
Location	Trials
Canada	1
Brazil	1
Italy	1
China	1

Clinical Trial Progress for RANITIDINE BISMUTH CITRATE

Clinical Trial Phase

Clinical Trial Phase for RANITIDINE BISMUTH CITRATE
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for RANITIDINE BISMUTH CITRATE
Clinical Trial Phase	Trials
Completed	3
Unknown status	2

Clinical Trial Sponsors for RANITIDINE BISMUTH CITRATE

Sponsor Name

Sponsor Name for RANITIDINE BISMUTH CITRATE
Sponsor	Trials
Canadian Institutes of Health Research (CIHR)	1
Drug Safety and Effectiveness Network, Canada	1
Canadian Network for Observational Drug Effect Studies, CNODES	1

Sponsor Type

Sponsor Type for RANITIDINE BISMUTH CITRATE
Sponsor	Trials
Other	8
Industry	1

Last updated: May 7, 2026

Ranitidine Bismuth Citrate: Clinical Trials Update, Market Analysis, and Projection

What is ranitidine bismuth citrate (RBC)?

Ranitidine bismuth citrate is a fixed-dose combination intended to deliver a histamine H2-receptor antagonist (ranitidine) plus bismuth. The product is used in regimens for upper gastrointestinal indications, most commonly peptic ulcer disease and related acid-peptic disorders, where bismuth provides mucosal protection and ranitidine suppresses gastric acid.

Key constraint shaping the market and clinical landscape: ranitidine (including formulations containing ranitidine) faced major regulatory disruption due to contamination concerns tied to NDMA (N-nitrosodimethylamine). That disruption materially reduced commercial availability and clinical momentum across the class.

---

What does the clinical trials landscape show?

Clinical-trials reality: The active development and new clinical expansion for ranitidine bismuth citrate has largely stalled in the wake of ranitidine’s regulatory setbacks. The available public trial record and downstream activity are dominated by legacy-era studies, label evaluations, and comparative or maintenance evidence rather than new, prospective phase programs.

Portfolio posture inferred from the market outcome:

• No meaningful current phase 3 or phase 2 late-stage pipeline growth appears to be driving new global approvals for RBC specifically.
• Where ranitidine remains in any capacity in markets, it is typically limited to legacy access or substitution by newer H2-receptor antagonists or alternative acid-suppressing strategies.

Operational implication for R&D planning:

• RBC should be treated as a mature, legacy combination with limited forward clinical optionality unless a sponsor has already secured a clear regulatory path for ranitidine-containing products in the target jurisdiction.

---

What is the market context for ranitidine bismuth citrate?

Market demand structure RBC demand historically tracked two drivers:

1. Acid-peptic disease prevalence in populations using H2-blocker strategies.
2. Formulary preference for combination regimens where bismuth addition supports peptic ulcer treatment paradigms.

Regulatory and supply shock

• The major commercial constraint is ranitidine’s removal or restriction across multiple jurisdictions following NDMA concerns. That shock reduces:
  • supply continuity for ranitidine-containing products,
  • prescribing confidence across hospitals and primary care,
  • pharmacy stocking and payer reimbursement stability,
  • new trial recruitment and sponsor willingness to invest in ranitidine-based development.

Competitive substitution Clinicians shifted toward alternatives, typically including:

• Proton pump inhibitors (PPIs) for acid suppression,
• Other H2-receptor antagonists where available and not similarly restricted,
• Bismuth-based non-ranitidine regimens used in Helicobacter pylori management pathways and ulcer therapy combinations (depending on local guidance).

Commercial conclusion RBC has a shrinking addressable market because the core component (ranitidine) lost broad regulatory runway. As a result, the RBC market behaves less like an active growth category and more like a diminishing legacy segment.

---

Where does RBC sit in the competitive landscape?

Substitution matrix (high-level) | Adjacent class | What it competes for | Typical substitution direction | |---|---|---| | PPIs | Ulcer healing, acid control, dyspepsia | Primary replacement for acid-peptic therapy | | Other H2 blockers (non-ranitidine) | Intermediate acid suppression | Limited replacement where H2 is preferred | | Bismuth-based H. pylori regimens | Ulcer-related microbial protocols | Component substitution for bismuth role |

Net effect: RBC’s differentiation (bismuth plus ranitidine) weakened as ranitidine access declined.

---

How should investors and business teams project the RBC market?

Because RBC is tightly bound to ranitidine’s regulatory status, projection should follow two scenario tracks: (A) continued restriction with limited legacy access versus (B) any re-expansion of ranitidine access. Given the observed regulatory outcome trajectory for ranitidine, RBC projections skew toward Scenario A.

Scenario A (base case): continued ranitidine restriction

Expected market path

• Revenue declines tied to product discontinuation, limited remaining inventories, and substitution by PPIs and other agents.
• Volume compression through reduced dispensing and formulary removal.
• Low likelihood of new market entrants because future development risk stays high.

Projection framing

• Use a “legacy demand decay” model rather than a growth curve.
• The installed base erodes as prescribers and pharmacies replace RBC with alternative regimens.

Scenario B (low probability): ranitidine access re-expands in key jurisdictions

Expected market path

• Short-term rebound only where reimbursement and supply restart.
• Demand lags because clinicians often lock into newer protocols and guidelines.
• Regulatory and pharmacovigilance requirements could slow uptake even if access returns.

Business implication: Any upside depends more on regulatory clearance and supply chain restart than on new clinical evidence for RBC.

---

What do regulatory events imply for RBC commercial value?

Ranitidine’s NDMA issue led to major regulatory actions, including withdrawals and/or restrictions by regulators in key markets. Those actions directly suppress RBC because it contains ranitidine.

Regulatory anchor points

• U.S. action: the FDA requested ranitidine manufacturers to withdraw ranitidine products from the market in April 2020 due to NDMA contamination concerns. (See FDA communications.)
• EU/UK and other jurisdictions implemented varying forms of restriction, withdrawals, and safety reviews, depending on local assessments and product-specific outcomes. (See MHRA and EMA-related guidance and national notices.)

Implication for RBC

• Even where bismuth is still used and supported in ulcer and H. pylori regimens, RBC cannot realize the same utility without ranitidine availability and regulatory clearance.

---

RBC: investment-grade market outlook summary (data-driven posture)

Given the regulatory constraint on ranitidine, RBC’s market outlook is best modeled as a sunset commodity rather than an innovation category.

Projection outcomes (directional)

• Base case: steady decline, with the tail driven by residual legacy supply and narrow clinical inertia.
• Bull case: limited rebound if ranitidine-containing products are reintroduced with NDMA-controlled supply and reinstated reimbursement, but RBC still faces guideline-driven substitution risk.

Actionable strategy

• Treat RBC as a legacy asset for any R&D planning, business development, or portfolio decisions unless there is an identified, jurisdiction-specific regulatory path that restores ranitidine’s market position.
• If the business objective is “bismuth-based ulcer therapy,” shift development and commercialization focus to bismuth-centric formulations not dependent on ranitidine exposure.

---

Key Takeaways

1. Ranitidine bismuth citrate’s forward clinical and commercial momentum is constrained by ranitidine’s NDMA-driven regulatory disruption, which suppresses supply, prescribing, and new development activity.
2. The active trial pipeline for RBC does not show the characteristics of a growing late-stage asset; the record is dominated by legacy-era evidence with limited new late-phase traction.
3. Market projection should follow a legacy demand decay model (base case), with any rebound tied primarily to regulatory and supply restoration for ranitidine in specific jurisdictions.

---

FAQs

1) Is there an active phase 3 development pipeline for ranitidine bismuth citrate today?

The current public development posture is consistent with legacy evidence rather than active late-stage global expansion for RBC.

2) Does bismuth component risk affect RBC independently of ranitidine?

No. The decisive market risk for RBC tracks ranitidine’s regulatory status tied to NDMA concerns, while bismuth remains used in ulcer and H. pylori related regimens.

3) What is the closest therapeutic substitution if RBC availability is reduced?

Clinicians typically switch to PPIs for acid-peptic control and to bismuth or guideline-based regimens for H. pylori and ulcer protocols, depending on indication.

4) Can RBC’s market recover if ranitidine re-enters major markets?

Recovery depends on reinstated regulatory clearance and stable NDMA-controlled supply. Even with access, demand may remain constrained by guideline substitution toward PPIs.

5) Is RBC a good candidate for new R&D investment?

As a ranitidine-dependent combination, RBC has structurally limited runway unless a defined regulatory pathway for ranitidine-containing products is established in the target geography.

---

References

[1] U.S. Food and Drug Administration (FDA). “FDA requests drug manufacturers withdraw all ranitidine products (Zantac) from the market.” April 2020.
[2] U.K. Medicines and Healthcare products Regulatory Agency (MHRA). “Ranitidine: NDMA contamination and regulatory updates.” 2020.
[3] European Medicines Agency (EMA). Communications and assessment updates related to ranitidine and NDMA (2020).
[4] World Health Organization (WHO). Background materials and international safety communications on NDMA-related contamination concerns for ranitidine (2020).